Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Myeloid 1Genitourinary 1

Conditions

Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Dexamethasone 124daratumumab 73Lenalidomide 72Bortezomib 61pomalidomide 45Cyclophosphamide 41carfilzomib 40Calcium Dobesilate 36Specimen Handling 34Biopsy 30Magnetic Resonance Spectroscopy 27belantamab mafodotin 24isatuximab 20fludarabine 20dexamethasone acetate 18dexamethasone 21-phosphate 18auricularum 18Melphalan 18talquetamab 16iberdomide 16fludarabine phosphate 12selinexor 11elotuzumab 10X-Rays 10tocilizumab 9Nivolumab 8Sirolimus 7Crizotinib 7trametinib 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
piperine × Plasma cell × 90 days × Clear all
NCT04731844 2026-05-12

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

University of Rochester

Phase 2 Completed
30 enrolled 13 charts
GenitourinaryPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡